Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Buserelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.67 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.56 |
| ▸ | APLNR | P35414 | 4/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buserelin SCHEMBL21806129 | 1.00 | ABCC2 (0.70) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Buserelin SCHEMBL14193133 | 0.99 | GNRHR (0.68) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Buserelin SCHEMBL13354 | 0.99 | GNRHR (0.68) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Buserelin SCHEMBL6676660 | 0.99 | GNRHR (0.68) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Buserelin SCHEMBL29833854 | 0.99 | GNRHR (0.68) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Buserelin SCHEMBL16766450 | 0.99 | GNRHR (0.68) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Goserelin SCHEMBL8836302 | 0.97 | GNRHR (0.66) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| SCHEMBL29833903 | 0.97 | GNRHR (0.64) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Buserelin SCHEMBL2544038 | 0.96 | ABCC2 (0.76) | ABCC2GNRHRPTGS1APLNR | |
| Goserelin SCHEMBL22367929 | 0.96 | ABCC2 (0.64) | ABCC2GNRHRPTGS1C5AR1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3649 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025118074-A1 | OLFACTORY DELIVERY OF THERAPEUTIC PEPTIDES | ROCKET SCIENCE HEALTH CORP. (CA) | 2025-06-12 | — | — | WO | claimed |
| CN-116731123-A | Method for purifying buserelin acetate | 河南美森药业有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-115137697-A | D-chlorprostenol sodium injection and preparation method and application thereof | 浙江科瑞特生物科技有限公司 | 2022-10-04 | — | — | CN | claimed |
| EP-3389690-B1 | FORMULATIONS AND METHODS FOR CONTROLLING THE REPRODUCTIVE CYCLE AND OVULATION | PROINVET INNOVATIONS S A (AR) | 2021-07-07 | — | — | EP | claimed |
| US-20210106538-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-04-15 | — | — | US | claimed |
| CN-109700780-B | Hydrophilic drug sustained-release microspheres with high encapsulation rate and preparation method thereof | 浙江圣兆药物科技股份有限公司 | 2021-02-12 | — | — | CN | claimed |
| US-20200376002-A1 | Injectable Hormone Formulations for Estrous Cycle Control in Mammals, its Manufacturing Process, Estrous Cycle Control and Puberty Triggering Methods, and Pregnancy Enhancement in Mammals | Applied Technologies Consultants Inc. (US) | 2020-12-03 | — | — | US | claimed |
| CN-111544569-A | Buserelin acetate freeze-dried powder injection for animal injection and preparation method and application thereof | 吉林吉力生物技术研究有限公司 | 2020-08-18 | — | — | CN | claimed |
| EP-2582371-B1 | METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES | ENDORECHERCHE INC (CA) | 2019-10-16 | — | — | EP | claimed |
| CN-109700780-A | A kind of water-soluble drug sustained release microsphere of high encapsulation rate and preparation method thereof | 浙江圣兆药物科技股份有限公司 | 2019-05-03 | — | — | CN | claimed |
| US-6265393-B1 | CONTINUOUS COADMINISTRATION OF LOW DOSES OF AN ESTROGEN AGENT AND A PROGESTIN AGENT TO MAINTAIN AN INDUCED STATE OF OLIGOMENORRHEA OR AMENORRHEA IN AN AFFLICTED WOMAN. | HEINRICHS WILLIAM LEROY (US) | 2001-07-24 | — | — | US | claimed |
| US-6096764-A | ELIMINATING THE DETRIMENTAL SIDE-EFFECTS ASSOCIATED WITH THE CONTINUOUS AND CHRONIC USE OF GONDATROPIN-RELEASING HORMONE FACTOR OR AGONIST BY ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF BENZOTHIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-08-01 | — | — | US | claimed |
| WO-2000040259-A1 | PROLONGED RELEASE MICROSPHERE ENCAPSULATING LUTEINIZING HORMONE-RELEASING HORMONE ANALOGUES AND METHOD FOR PREPARING THE SAME | DONG KOOK PHARMACEUTICAL CO., LTD. (KR) | 2000-07-13 | — | — | WO | claimed |
| WO-2000007599-A1 | PREVENTION OF ENDOMETRIOSIS SIGNS OR SYMPTOMS | HEINRICHS WILLIAM LEROY (US) | 2000-02-17 | — | — | WO | claimed |
| US-5942242-A | A MEDICAMENT SUSPENSION OR POWDER FOR NASAL ADMINISTRATION TO DELIVER A VACCINE OR ACTIVE PEPTIDE ACROSS THE MUCOUS MEMBRANE, COMPRISING CATION EXCHANGE RESINS POWDER POLYSTYRENE-SULFONATES, POLYSTYRENE-ACID COPOLYMERS AND SALTS | LTT INSTITUTE CO., LTD (JP) | 1999-08-24 | — | — | US | claimed |
| WO-1999008677-A1 | METHODS FOR INHIBITING DETRIMENTAL SIDE-EFFECTS DUE TO GnRH OR GnRH AGONIST ADMINISTRATION | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| EP-0897721-A2 | Benzo(b)thiophene derivatives for inhibiting detrimental side-effects due to GnRH or GnRH agonist administration | ELI LILLY AND COMPANY (US) | 1999-02-24 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0845265-A1 | MUCOSAL PREPARATION CONTAINING PHYSIOLOGICALLY ACTIVE PEPTIDE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-06-03 | — | — | EP | claimed |
| EP-0505966-B1 | Long-acting biodegradable microparticles and process for preparation | HOECHST AG (DE) | 1995-06-28 | — | — | EP | claimed |